ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity

@article{Harrington2015ACP196IA,
  title={ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity},
  author={B. Harrington and M. Gulrajani and T. Covey and A. Kaptein and B. Lith and R. Izumi and A. Hamdy and R. Ulrich and J. Byrd and B. Lannutti and A. Johnson},
  journal={Blood},
  year={2015},
  volume={126},
  pages={2908-2908}
}
  • B. Harrington, M. Gulrajani, +8 authors A. Johnson
  • Published 2015
  • Medicine
  • Blood
  • Background: Signaling through the B-cell receptor (BCR) results in cell survival and proliferation, and this pathway is critical for the progression of many B-cell malignancies, such a chronic lymphocytic leukemia (CLL). BTK, a TEC family kinase, is essential to the BCR signaling cascade. The recent approval of the first-in-class BTK inhibitor for the treatment certain B-cell malignancies, ibrutinib, has validated BTK as a clinical target. ACP-196 is a novel, second generation inhibitor of BTK… CONTINUE READING
    14 Citations

    Topics from this paper.

    Second-generation inhibitors of Bruton tyrosine kinase
    • 89
    Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
    • 96
    Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors
    • 12
    Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors
    • 3
    An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma
    • 3
    Future therapeutic options for patients with Waldenström macroglobulinemia.
    • 4
    • Highly Influenced
    • PDF
    Acalabrutinib: First Global Approval
    • 13
    • Highly Influenced